XORTX Therapeutics (XRTX) Receivables - Net (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Receivables - Net came in at $64633.0 in Q1 2026, up 274.64% YoY from $17252.0 in Q1 2025, and down 19.38% on a QoQ basis from $80172.0 in Q4 2025.
XORTX Therapeutics (XRTX) Receivables - Net (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Receivables - Net data on file, last reported at $64633.0 in Q1 2026.
- Quarterly Receivables - Net rose 274.64% year-over-year to $64633.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64633.0 (up 274.64% YoY) and the FY2025 annual result came in at $80172.0, up 354.57% from the prior year.
- Receivables - Net fell to $64633.0 in Q1 2026, from $80172.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $195583.2 in Q2 2022 to a low of $10860.0 in Q2 2025.
- A 5-year average of $55395.9 and a median of $36421.0 in 2023 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2023 — Receivables - Net slumped 84.45% — and 2025, when it surged 354.57%.
- Tracing XRTX's Receivables - Net over 5 years: stood at $81575.1 in 2022, then retreated by 25.58% to $60711.0 in 2023, then plunged by 70.95% to $17637.0 in 2024, then jumped by 354.57% to $80172.0 in 2025, then retreated by 19.38% to $64633.0 in 2026.
- The last three Receivables - Net figures came in at $64633.0 (Q1 2026), $80172.0 (Q4 2025), and $22092.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64,633.00 |
| Mar 31, 2026 | 64,633.00 |
| Dec 31, 2025 | 80,172.00 |
| Dec 31, 2025 | 80,172.00 |
| Sep 30, 2025 | 22,092.00 |
| Sep 30, 2025 | 22,092.00 |
| Jun 30, 2025 | 10,860.00 |
| Jun 30, 2025 | 10,860.00 |
| Mar 31, 2025 | 17,252.00 |
| Mar 31, 2025 | 17,252.00 |
| Dec 31, 2024 | 17,637.00 |
| Dec 31, 2024 | 17,637.00 |
| Sep 30, 2024 | 13,111.00 |
| Sep 30, 2024 | 13,111.00 |
| Jun 30, 2024 | 22,807.00 |
| Jun 30, 2024 | 22,807.00 |
| Mar 31, 2024 | 30,883.00 |
| Mar 31, 2024 | 30,883.00 |
| Dec 31, 2023 | 60,711.00 |
| Dec 31, 2023 | 60,711.00 |